Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.97 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.97 |
| ▸ | THPO | P40225 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.74 |
| ▸ | GMNN | O75496 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235082 | 1.00 | MEN1 (0.97) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Hydrochloric Acid SCHEMBL5498548 | 0.98 | MEN1 (0.94) | MEN1KMT2AMAPTSLC25A20TP53 | |
| Octanoylcarnitine SCHEMBL2915508 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL19182624 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL17164609 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL25373354 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL8050598 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL288242 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL188470 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 | |
| SCHEMBL288673 | 0.98 | MAPT (1.00) | MEN1KMT2AMAPTSLC25A20TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | INNOBATION BIO CO LTD (KR) | 2026-04-30 | — | — | US | claimed |
| US-12493041-B2 | Apparatus for diagnosing solid cancers and method for providing information on solid cancer diagnosis | INNOBATION BIO CO., LTD. (KR) | 2025-12-09 | — | — | US | claimed |
| EP-4597100-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | Innobation Bio Co., Ltd. (KR) | 2025-08-06 | — | — | EP | claimed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024071740-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | (주)이노베이션바이오 | 2024-04-04 | — | — | WO | claimed |
| WO-2023249252-A1 | BIOMARKERS FOR LUNG CANCER DIAGNOSIS AND METHOD FOR PROVIDING ARTIFICIAL INTELLIGENCE-BASED INFORMATION ON LUNG CANCER DIAGNOSIS | (주)이노베이션바이오 | 2023-12-28 | — | — | WO | claimed |
| CN-116994762-B | Construction method and application of M Index model for MMDS auxiliary diagnosis | 中山大学附属第六医院 | 2023-12-22 | — | — | CN | claimed |
| CN-116994762-A | Construction method and application of M Index model for MMDS auxiliary diagnosis | 中山大学附属第六医院 | 2023-11-03 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-115684430-A | Application of nasopharyngeal carcinoma related serum marker in preparation of product for diagnosing/prognosing nasopharyngeal carcinoma | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | 2023-02-03 | — | — | CN | claimed |
| US-20220349895-A1 | APPARATUS FOR DIAGNOSING SOLID CANCERS AND METHOD FOR PROVIDING INFORMATION ON SOLID CANCER DIAGNOSIS | INNOBATION BIO CO., LTD. (KR) | 2022-11-03 | — | — | US | claimed |
| EP-4027139-A2 | APPARATUS FOR DIAGNOSING SOLID CANCERS AND METHOD FOR PROVIDING INFORMATION ON SOLID CANCER DIAGNOSIS | Innobation Bio Co., Ltd. (KR) | 2022-07-13 | — | — | EP | claimed |
| CN-113939737-A | Solid cancer diagnosis device and method for providing solid cancer diagnosis information | 创新生物有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2020204373-A2 | APPARATUS FOR DIAGNOSING SOLID CANCERS AND METHOD FOR PROVIDING INFORMATION ON SOLID CANCER DIAGNOSIS | 국립암센터 | 2020-10-08 | — | — | WO | claimed |
| EP-0517125-A1 | Use of propionyl L-carnitine for regaining muscle tone in immobilised patients | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-12-09 | — | — | EP | claimed |
| JP-5155766-A | — | — | None | — | — | JP | disclosed |
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | INNOBATION BIO CO LTD (KR) | 2026-04-30 | — | — | US | disclosed |
| JP-H05155766-A | ACYL-L-CARNITINE PHARMACEUTICAL COMPOSITION FOR REGAINING MUSCLE TONE | SIGMA TAU IND FARMACEUT RIUNITE SPA | 1993-06-22 | — | — | JP | disclosed |
| EP-0517125-A1 | Use of propionyl L-carnitine for regaining muscle tone in immobilised patients | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-12-09 | — | — | EP | disclosed |
| EP-0480676-A2 | Acyl carnitine esterase, production thereof and method for analyzing acyl carnitines | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260120870-A1 | ARTIFICIAL INTELLIGENCE-BASED INFORMATION PROVISION METHOD FOR DIAGNOSING LUNG CANCER BY USING BIOMARKER FOR LUNG CANCER DIAGNOSIS AND CLINICAL INFORMATION OF TEST SUBJECT | KYNU, CPT2, CPT1A | MEN1 1628/4885KMT2A 564/4885MAPT 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.